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Abstract
Recently, fimbriae have been identified as a possible arising site for the pelvic serous carcinoma
(PSC) both in BRCA-positive and BRCA-negative women. Although non-invasive (intraepithelial)
serous adenocarcinoma of the fimbria has been found in specimens obtained from prophylactic
salphingo-oophorectomies in BRCA-positive women, there has not been any case report in clinical
situation, since this type of tumor is usually detected after stromal invasion/widespread
dissemination. We describe a 67-year-old woman with non-invasive serous adenocarcinoma
located solely in the left fimbria. This case may suggest the benefit of endometrial cytology and
detailed gross examination of fimbria for the early detection of fimbrial carcinoma. This case may
provide evidence suggesting fimbrial intraepithelial adenocarcinoma is one cause of PSC.
Background
Pelvic serous carcinoma (PSC) has been presumed to arise
in three different locations in the female pelvis [1]: the
ovary (serous ovarian carcinoma), the endosalpinx
(serous fallopian tube carcinoma) and on the peritoneal
surface (primary peritoneal serous carcinoma). Among
the three, primary cancer of the fallopian tube has previ-
ously been estimated to be very rare [2].
Recently, tubal fimbriae have been shown as the common
site for early PSC (intraepithelial carcinoma) in women
with BRCA mutations [3]. Also, the potential role of the
fimbriae in primary PSC has been suggested [4,5], irre-
spective of BRCA-status. A few case of fimbrial adenocar-
cinoma, though invasive, has also been reported in
surgical material resected for benign gynecological tumor
at other sites [6].
We present a case of PSC caused by non-invasive serous
adenocarcinoma involving the unilateral fimbria. To our
knowledge, this is the first case report describing non-
invasive, serous adenocarcinoma originating in the fim-
bria and spreading to the pelvic/intrauterine cavity in a
clinical situation.
Case presentation
A 67-year-old Japanese women, gravida 2, para 2, visited
our hospital for regular (once 2 years) gynecologic screen-
ing. She had no family history for ovarian/breast carci-
noma. There were no remarkable findings on physical
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cytology demonstrated abundant nests of adenocarcino-
matous cells with peripherally located nuclei among
sheets of non-atypical endometrial cells (Fig. 1A).
Endometrial biopsy resulted in insufficient materials with
only a few atypical cells. Abdominopelvic CT/MRI did not
show enlargement of bilateral adnexa, endometrial thick-
enings lymphadenopathy, or ascites. Blood tests includ-
ing tumor markers, CA125, CA19-9, and CEA were all
within normal limits.
Because of the cytology/biopsy findings, hysterectomy
and bilateral salphingo-oophorectomy with sampling of
intra - pelvic lymph nodes were performed. During sur-
gery, there were no visible lesions in the abdominopelvic
space with only a small amount of yellowish to slightly
muddy ascites. However, intraoperative cytology of the
ascites demonstrated many adenocarcinoma nests (Fig.
1B).
The surgical specimen showed bilateral, normal - appear-
ing ovary and uterus with smooth/thin endometrium and
a few myoma (Fig. 2A). There was no sign of disseminated
tumor. Interestingly, compared to the right fimbrial ende,
the left one was composed of shorter/dense fimbria when
observed from the back-side (Fig. 2B, C).
Cytology of the tumorFigure 1
Cytology of the tumor. (A) Endometrial cytology shows 
nests of atypical cells among the sheets of well-organized, 
non-atypical endometrial cells. (B) Intraoperative cytology of 
the ascites shows abundant atypical cells with peripherally-
located and pleomorphic nuclei in clear background. [Papani-
calau stain, A; × 40, B; ×60]
Macroscopic findings of the surgical specimenFigure 2
Macroscopic findings of the surgical specimen. (A) 
Front view of uterus and bilateral adnexa shows no remarka-
ble findings except a few myoma in the uterine corpus. (B) 
Back view of left fimbrial ende shows shorter/denser fimbria 
compared to the right one. (C) Back view of the right fim-
brial ende.Page 2 of 4
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was on gross inspection, the whole surgical specimen was
cut into histological section, in order to find the origin of
the tumor. Bilateral adnexae except fimbria were cut into
section at 5 mm intervals and each fimbriated end was cut
sagitally into two.
Pathologically, intraepithelial, non-invasive adenocarci-
noma was found solely in the left fimbria (Fig. 3A-C).
There was no tumor in the uterine cavity, right adnexa,
lymph nodes, or left adnexa other than the fimbriated
end. Immunohistochemically, adenocarcinoma was posi-
tive for p53 (Fig. 3D) and negative for calretinin/mesothe-
lin. At the periphery of the left fimbrial ende, more than
12 normal - appearing nonciliated epithelial cells were
positive for p53 in a consecutive fashion, so-called "p53
signatures" [7] (Fig. 3E, F).
Discussion
Assignment of the primary site for PSCs is often problem-
atic, since these lesions are usually discovered after
spreading to the peritoneal surfaces. Our case was diag-
nosed to be tubal, especially, of fimbrial-origin. Surpris-
ingly, despite the 'non-invasive' stage, our case showed
spread to the peritoneal/intrauterine cavity, suggesting the
ability of this type of tumor to spread rapidly. Although
the peritoneum was not at all resected during surgery, the
peritoneal surface is unlikely to have been primary site in
our case for the following reasons. (1) There was no
grossly suspicious lesion observed during the surgery. (2)
Diffuse replacement of the fimbrial epithelium by the
tumor and existence of a p53 signature may support the
fimbria as the primary site. Only the co-exsistence of p53
signature may not be a strong evidence for its primary site
without genetic testing, the diffuse replacement of the
tumor suggested 'primary' rather than 'implantation'.
Until recently, most pathologists have not customarily
examined the entire fallopian tube in cases of pelvic
serous carcinoma, but rather only a perfunctory section of
the central fallopian tube. Lee et al. [8] developed a proto-
col for sectioning and extensively examining the fimbri-
ated end (SEE-FIM) to examine adnexal lesions
thoroughly. They proposed application of this protocol to
BRCA+ patients, patients with a family history of ovarian/
breast cancer, and epithelial malignancies of the repro-
ductive tract. We again recommend examining the fim-
briae in PSC cases. As for the examination of routine
hysterectomy cases, we think, it may be reasonable to
examine bilateral fimbriae and 1 or 2 sections of bilateral
tube.
As far as we know, there has no case report of serous ade-
nocarcinoma of the fimbria at non-invasive (intraepithe-
lial) stage, except prophylactically operated cases. In this
case, the endometrial cytology contributed in the earlier
detection of the fimbrial carcinoma.
In our case, there was a marked gross difference between
the left fimbria (with adenocarcinoma) and the right fim-
bria (without), when seen observed from the back side.
Detailed gross examination may be helpful for the early
detection of fimbrial carcinoma. In our routine work,
because of the surgical procedure, fimbriae are sometimes
very much congested when submitting to pathological
department. Earlier observation of fimbriae may be rec-
ommendable for their detailed gross examination.
Conclusion
Clinical case detecting fimbrial adenocarcinoma at
intraepithelial stage is very rare. This case report may sug-
gest the benefit of endometrial cytology, detailed exami-
nation of fimbria, and may provide evidence suggesting
Histological findings of the left fimbriated endeFigure 3
Histological findings of the left fimbriated ende. (A) 
Low - power view shows lining of enlarged cells at fimbrial 
surface with slightly thickened stroma. (B) High - power view 
shows serous adenocarcinoma in micropapillary structure. 
(C and D) Tumor cells shows immunopositive for P53. Fig. 
3C and 3D are from the same site. (E and F) So-called p53 
signature is seen at the periphery of the left fimbrial ende. 
Fig. 3E and 3F are from the same site. As seen in the Inset of 
E, p53-positive cells are composed of seemingly, non-cancer-
ous cells. [A; H&E, ×4, B; H&E, ×40, C: H&E, ×15, D; Immu-
nohistochemistry for p53, ×15, E: H&E, ×10, F: 
Immunohistochemistry for p53, ×10].Page 3 of 4
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fimbrial intraepithelial adenocarcinoma is one cause of
PSC.
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